Babesia Clinical Diagnosis When Tests Fail

Babesia clinical diagnosis may be necessary when laboratory tests fail to confirm infection.

When Laboratory Confirmation Fails Clinical Reality

Investigators from ISDH and the Centers for Disease Control and Prevention (CDC) examined specimens from 14 patients diagnosed with Lyme disease and B. microti. They tested for Babesia infection by Giemsa-stained blood smears, PCR, and indirect fluorescent antibody (IFA) testing for total immunoglobulin to B. microti.

The only clinical manifestation consistent with Lyme disease included unspecified rashes in 3 patients. Anemia and fever, symptoms associated with Babesia, were identified in 2 patients.

---

None Met CDC Surveillance Criteria

Investigators concluded that none of the patients “fulfill the national surveillance case definition for non–transfusion-associated babesiosis,” writes Brown from ISDH.

Two of the 12 patients had a B. microti IFA titer of 1:64, but this is considered insufficient evidence by the CDC for a Babesia diagnosis. All other testing was negative.

The CDC and ISDH concluded that their “laboratory-based investigation does not suggest a cluster of Lyme disease or babesiosis cases among these patients.”

This creates an important clinical question: were the original diagnoses wrong, or was the laboratory investigation poorly timed to detect infection?

---

Why Babesia Tests Can Be Negative

There are several reasons why laboratory confirmation of B. microti may fail.

First, specimens were collected long after symptom onset, when blood smears and PCR would often be negative.

“Patient specimens were collected a median of 172 days (range = 22–348 days) after reported illness onset date,” writes Brown.

This timing matters. PCR detects circulating Babesia DNA, and blood smears depend on visible parasitemia. Months after onset—especially after treatment—parasite levels may be too low to detect.

---

Treatment Effects on Laboratory Results

Investigators also evaluated serologic specimens after patients had already received an average of 3 antimicrobial agents.

Treatment and delayed testing may have altered laboratory results. If patients had received atovaquone and azithromycin, parasite burden could have declined enough to make PCR and blood smears negative.

Although antibodies may persist after treatment, titers may not meet the CDC surveillance threshold of 1:256. Two patients had titers of 1:64, suggesting possible exposure that did not meet reporting criteria.

---

Limitations of the Investigation

Investigators did not fully examine the clinical factors that led physicians to diagnose Babesia.

“ISDH did not conduct patient interviews or chart reviews; demographic and clinical data were obtained from the CDC specimen submission form,” states Brown.

This is a major limitation. The treating physicians may have relied on exposure history, symptom pattern, treatment response, and supporting laboratory findings. None of this clinical context was fully reviewed.

---

When Babesia Clinical Diagnosis Is Appropriate

Brown concludes that Lyme disease and babesiosis should be considered in the differential diagnosis for patients with compatible illness and exposure to I. scapularis ticks.

This case series underscores the importance of not relying solely on laboratory confirmation when tick-borne co-infections are suspected, especially when testing is delayed or patients have already been treated.

The findings support an important clinical point: Babesia diagnosis may depend on clinical judgment, not just surveillance-based laboratory criteria.

---

CDC Surveillance Criteria vs Clinical Diagnosis

The CDC surveillance definition for babesiosis requires parasites on blood smear, a positive PCR, or an IFA antibody titer of at least 1:256.

These criteria were designed for public health surveillance, not for individual clinical care.

Clinical diagnosis is different. When a patient has compatible symptoms, exposure risk, and suggestive findings, Babesia may still be the correct diagnosis even if formal surveillance criteria are not met.

---

Frequently Asked Questions

Can you have Babesia with negative laboratory tests?
Yes. Testing may be negative if it is delayed, if parasitemia is low, or if the patient has already received treatment.

Why would Babesia tests be negative after treatment?
Treatment can reduce parasite burden enough to make PCR and blood smears negative.

When should doctors make a clinical Babesia diagnosis?
When patients have compatible symptoms, possible tick exposure, and a clinical picture consistent with Babesia, even if testing is negative.

What is the difference between CDC surveillance criteria and clinical diagnosis?
CDC criteria are meant for case reporting. Clinical diagnosis considers the full picture, including symptoms, exposure, labs, and response to treatment.

Should Babesia treatment wait for positive lab results?
Not always. If suspicion is high, empiric treatment may be reasonable.

---

Clinical Takeaway

Babesia can remain a clinical diagnosis when delayed or post-treatment testing turns negative.

---

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention